FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2071602450> ?p ?o ?g. }

• W2071602450 endingPage "254" @default.
• W2071602450 startingPage "243" @default.
• W2071602450 abstract "In this work human platelet aggregation induced in vitro by ADP, collagen, arachidonic acid and U-46619 (a thromboxane A(2) analogue) was used as a functional test to characterize 19 anti-GPIIb (M series) and anti2 GPIIIa (P series) monoclonal antibodies whose epitope location is known for most of them. Additionally, flow cytofluorimetry was applied to study the epitope expression of these antibodies in resting, EDTA-treated and SFLLRN peptide (thrombin receptor agonist)-activated platelets. Antibodies M6 (epitope located at GPIIbH 657-665), P23-7 (GPIIIa 114-122) and P40 (GPIIIa 262-303) bind weakly to only 43%, 70% and 66%, respectively, of the resting platelet population. This binding was enhanced in EDTA-treated and in activated platelets. Platelet activation enhances the apparent binding of most of the other antibodies. Further evidence on the existence of agonist-specific activated states of GPIIb/IIIa was provided by the agonist-dependent immunochemical inhibition in vitro of platelet aggregation by some of the anti-subunit antibodies studied here. The most notable cases are those of P40 and M6, which at 140 nM inhibit most, the platelet aggregation induced by arachidonic acid and U-46619. On the other hand, three of the most strong and agonist-independent inhibitors, P37 (GPIIIa 101-109), P97 and P95-2 (GPIIIa N-terminal half) bind to resting platelets with high affinity (5-8 nM), compete with each other for binding to GPIIb-IIIa and their epitopes are located at the N-terminal domain of GPIIIa, where the receptor ligand binding site(s) have been found. Given that the formation of activated GPIIb-IIIa (GPIIb-IIIa*) is the first step at which the anti-subunit antibodies can intervene as inhibitors and that agonist-specific inhibitors should block only agonist-specific steps, while nonspecific inhibitors should block steps common to all the agonists, then our present work support the hypothesis that there are different agonist-specific GPIIb-IIIa*s or, alternatively, different receptor environments, that can be specifically blocked by some of the antibodies. These results add to earlier evidence on agonist-dependent ligand specificity and activated states found for this and other integrins. Finally, the correlation between the in vitro inhibition of platelet aggregation and the antithrombotic activity in vivo is discussed for these antibodies." @default.
• W2071602450 created "2016-06-24" @default.
• W2071602450 creator A5016914416 @default.
• W2071602450 creator A5041154097 @default.
• W2071602450 creator A5044894064 @default.
• W2071602450 creator A5048114497 @default.
• W2071602450 creator A5061977662 @default.
• W2071602450 creator A5079922371 @default.
• W2071602450 date "1997-01-01" @default.
• W2071602450 modified "2023-10-18" @default.
• W2071602450 title "Functional characterization of GPIIb- and GPIIIa-specific monoclonal antibodies. Further evidence for the existence of agonist-specific activated states of the platelet fibrinogen receptor" @default.
• W2071602450 cites W1481395580 @default.
• W2071602450 cites W1482015283 @default.
• W2071602450 cites W1482855479 @default.
• W2071602450 cites W1486175763 @default.
• W2071602450 cites W1497766492 @default.
• W2071602450 cites W1557509594 @default.
• W2071602450 cites W1563119717 @default.
• W2071602450 cites W1566066927 @default.
• W2071602450 cites W1583875039 @default.
• W2071602450 cites W1593513931 @default.
• W2071602450 cites W1602471118 @default.
• W2071602450 cites W1656991593 @default.
• W2071602450 cites W1968205199 @default.
• W2071602450 cites W1979158754 @default.
• W2071602450 cites W1989161066 @default.
• W2071602450 cites W2009861657 @default.
• W2071602450 cites W203618348 @default.
• W2071602450 cites W2039012502 @default.
• W2071602450 cites W2049952782 @default.
• W2071602450 cites W2065155390 @default.
• W2071602450 cites W2070707394 @default.
• W2071602450 cites W2075300876 @default.
• W2071602450 cites W2076299040 @default.
• W2071602450 cites W2095361278 @default.
• W2071602450 cites W2113049699 @default.
• W2071602450 cites W2142432718 @default.
• W2071602450 cites W2149003800 @default.
• W2071602450 cites W2199935309 @default.
• W2071602450 cites W2239502490 @default.
• W2071602450 cites W2246336614 @default.
• W2071602450 cites W2340565246 @default.
• W2071602450 cites W2342669116 @default.
• W2071602450 cites W2385753138 @default.
• W2071602450 cites W2407299336 @default.
• W2071602450 cites W2410007954 @default.
• W2071602450 cites W2467624304 @default.
• W2071602450 cites W2617516516 @default.
• W2071602450 cites W637617399 @default.
• W2071602450 doi "https://doi.org/10.1080/09537109777285" @default.
• W2071602450 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16793655" @default.
• W2071602450 hasPublicationYear "1997" @default.
• W2071602450 type Work @default.
• W2071602450 sameAs 2071602450 @default.
• W2071602450 citedByCount "5" @default.
• W2071602450 crossrefType "journal-article" @default.
• W2071602450 hasAuthorship W2071602450A5016914416 @default.
• W2071602450 hasAuthorship W2071602450A5041154097 @default.
• W2071602450 hasAuthorship W2071602450A5044894064 @default.
• W2071602450 hasAuthorship W2071602450A5048114497 @default.
• W2071602450 hasAuthorship W2071602450A5061977662 @default.
• W2071602450 hasAuthorship W2071602450A5079922371 @default.
• W2071602450 hasConcept C153911025 @default.
• W2071602450 hasConcept C159654299 @default.
• W2071602450 hasConcept C170493617 @default.
• W2071602450 hasConcept C185592680 @default.
• W2071602450 hasConcept C195616568 @default.
• W2071602450 hasConcept C203014093 @default.
• W2071602450 hasConcept C2777292125 @default.
• W2071602450 hasConcept C2778938600 @default.
• W2071602450 hasConcept C3018697912 @default.
• W2071602450 hasConcept C542903549 @default.
• W2071602450 hasConcept C55493867 @default.
• W2071602450 hasConcept C86803240 @default.
• W2071602450 hasConcept C89560881 @default.
• W2071602450 hasConceptScore W2071602450C153911025 @default.
• W2071602450 hasConceptScore W2071602450C159654299 @default.
• W2071602450 hasConceptScore W2071602450C170493617 @default.
• W2071602450 hasConceptScore W2071602450C185592680 @default.
• W2071602450 hasConceptScore W2071602450C195616568 @default.
• W2071602450 hasConceptScore W2071602450C203014093 @default.
• W2071602450 hasConceptScore W2071602450C2777292125 @default.
• W2071602450 hasConceptScore W2071602450C2778938600 @default.
• W2071602450 hasConceptScore W2071602450C3018697912 @default.
• W2071602450 hasConceptScore W2071602450C542903549 @default.
• W2071602450 hasConceptScore W2071602450C55493867 @default.
• W2071602450 hasConceptScore W2071602450C86803240 @default.
• W2071602450 hasConceptScore W2071602450C89560881 @default.
• W2071602450 hasIssue "4" @default.
• W2071602450 hasLocation W20716024501 @default.
• W2071602450 hasLocation W20716024502 @default.
• W2071602450 hasOpenAccess W2071602450 @default.
• W2071602450 hasPrimaryLocation W20716024501 @default.
• W2071602450 hasRelatedWork W195682249 @default.
• W2071602450 hasRelatedWork W1981898410 @default.
• W2071602450 hasRelatedWork W2059923545 @default.
• W2071602450 hasRelatedWork W2063604066 @default.
• W2071602450 hasRelatedWork W2091594406 @default.

• next